Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.

Inclusion Criteria:

• Chinese healthy men or women aged 18 to 55 years old at screening (inclusive）;
• Serum LDL-C concentration between 1.8 mmol/L and 4.9 mmol/L (inclusive）at screening;
• Body mass index between 19 and 28 kg/m2 (inclusive);
• Willing to maintain the current regular diet and physical activity;
• Female subjects and male subject's partner who could become pregnant should take effective contraceptions during the treatment period and 6 months after dosing;
• Without any medical history of serious diseases;
• Willing to comply with protocol required visit schedule and visit requirements and provide written informed consent.

Exclusion Criteria:

• Breast-feeding or pregnant women;
• History of allergic reaction;
• Previously received any anti-PCSK-9 treatment;
• Vital signs, physical examination, clinical laboratory test, 12-lead ECG, and chest X-ray are abnormal with clinical significance;
• Not willing to stop intense physical activities (such as weight lifting or long-distance running) before 72 hours of the scheduled visits;
• Any hospitalization within one month before screening, or major surgery within six months before screening, or any other unstable medical condition;
• Received an investigational chemical agent within 30 days before dosing；
• Received an investigational biological agent within 90 days before dosing；
• Use of medications including over-the-counter medication within 14 days or less than 5 half-lifes of the agent;
• Use of herb,vitamins or nutraceutical in order to alter serum lipids;
• Positive screen of hepatitis B surface antigen, hepatitis C virus, human immunodeficiency virus or syphilis infection at screening；
• History or clinical evidence of alcohol or drugs of abuse within 12 months before screening;
• With any consumption of alcohol and caffeinated beverages within 72 hours prior to and during the trial;
• Blood donations or blood loss 200 ml and more within 2 months before screening;
• History of organ transplantation or malignant tumor;
• Any conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrollment.